Kairos Pharma Receives 2026 Healthcare Innovation Award for Drug Resistance Research
Kairos Pharma has been recognized with the 2026 GHP Magazine Healthcare & Pharmaceutical Award as the USA leader in drug resistance development, highlighting its work on cancer therapeutics that address treatment resistance.
Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award underscores the company's focus on advancing cancer therapeutics designed to overcome treatment resistance, a critical challenge in oncology that limits the effectiveness of existing therapies.
The award highlights Kairos Pharma's innovative approach to extending the utility of standard cancer treatments. The company's lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
ENV-105 is currently being evaluated in clinical trials. It is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. However, as of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The award from GHP Magazine is part of the 2026 Healthcare & Pharmaceutical Awards, which recognize leaders in healthcare innovation. For more details on the award, the full press release is available at https://ibn.fm/WuBOf.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's focus on drug resistance is particularly important given that resistance to cancer therapies is a major cause of treatment failure and disease progression. By developing therapies that target resistance mechanisms, Kairos Pharma aims to improve outcomes for patients with hard-to-treat cancers.
The recognition comes as the company continues to advance its clinical programs. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA.
This award highlights the growing importance of addressing drug resistance in cancer treatment. As more therapies are developed, the ability to overcome resistance will be crucial for improving patient survival and quality of life. Kairos Pharma's work in this area positions it as a key player in the ongoing effort to make cancer treatments more effective.